TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Option Overview for Mantle Cell Lymphoma
Source: Mantle Cell Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Once the diagnosis of mantle cell lymphoma (MCL) is established and staging is completed (usually with positron emission tomography–computed tomography, although colonoscopy, bone marrow biopsy, or lumbar puncture may be indicated in selected cases), laboratory testing is performed. This testing allows a distinction to be made among the indolent non-nodal leukemic subtype (20% of patients with MCL), the more aggressive nodal subtype, or the hyperaggressive blastoid or TP53-altered subtype which confers the worst prognosis. Clinical judgment may be required for patients with both indolent and aggressive features. For more information about laboratory testing, see the sections on Clinical Features and Stage Information for Mantle Cell Lymphoma.
Source links and citations
| MCL Subtype | Treatment Options | ||
|---|---|---|---|
| BR = bendamustine and rituximab; BTK = Bruton tyrosine kinase; CAR = chimeric antigen receptor; R2 regimen = rituximab and lenalidomide; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-DHAP = rituximab, dexamethasone, high-dose cytarabine, and cisplatin; R-HCVAD = rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; R-MA = rituximab, methotrexate, and cytarabine. | |||
| Non-nodal leukemic subtype: Early-stage (IA, IIA) stable or slowly progressing disease | Watchful waiting | ||
| Radiation therapy | |||
| Anti-CD20 monoclonal antibodies (rituximab, obinutuzumab) | |||
| BTK inhibitors (acalabrutinib) | |||
| R2 regimen | |||
| BR | |||
| Nodal aggressive subtype: Advanced-stage lymph nodes (stage IIB, III, IV) | BTK inhibitors with or without anti-CD20 monoclonal antibodies | ||
| Chemoimmunotherapy (BR; R-CHOP/R-DHAP; R-HCVAD/R-MA) | |||
| R2 regimen | |||
| Rituximab alone (in older patients with comorbidities who cannot take BTK inhibitors) | |||
| Hyperaggressive blastoid or TP53-altered subtype | BTK inhibitor + rituximab (or obinutuzumab) + BCL-2 inhibitor (venetoclax) | ||
| Consolidation with T-cell directed therapy such as allogeneic stem cell transplant, CAR T-cell therapy, or bispecific antibody therapy | |||
| Clinical trials | |||
Before beginning systemic therapy, patients should be screened for active hepatitis B, hepatitis C, or HIV.[1] Patients with detectable hepatitis B virus (HBV) benefit from prophylaxis with entecavir if their treatment plan includes rituximab, Bruton tyrosine kinase (BTK) inhibitors, or chemoimmunotherapy. Patients with a resolved HBV infection (defined as hepatitis B surface antigen-negative but hepatitis B core antibody-positive) are at risk of reactivation of HBV and require active monitoring of HBV DNA. For patients who received rituximab or obinutuzumab therapy, the risk of reactivation was 10% to 15%; prophylaxis reduced this risk to 2% in a retrospective study.[2] Similarly, prophylaxis for herpes zoster with valacyclovir or acyclovir and prophylaxis for pneumocystis with trimethoprim/sulfa or dapsone are usually given to all patients receiving systemic therapy.
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice